Open AccessTivozanib for hepatocellular carcinoma: not likely a new option
Author(s) -
Florian Estrade,
Fanny Le Du,
Laurence Crouzet,
Héloïse Bourien,
Léa Muzellec,
Julien Edeline
Publication year - 2020
Publication title -
annals of translational medicine
Language(s) - English
Resource type - Journals
eISSN - 2305-5847
pISSN - 2305-5839
DOI - 10.21037/atm-20-3389
Subject(s) - hepatocellular carcinoma , medicine , cancer research , bioinformatics , computational biology , biology
Medical Oncology, Centre Eugène Marquis, Rennes, France Correspondence to: Florian Estrade. Medical Oncology, Centre Eugène Marquis, Rennes, France. Email: f.estrade@rennes.unicancer.fr. Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine. The article did not undergo external peer review. Comment on: Fountzilas C, Gupta M, Lee S, et al. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer 2020;122:963-70.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom